Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients

Bei Hu; Xiao Lin; Hans C. Lee; Xuelin Huang; Rebecca S.Slack Tidwell; Kwang Woo Ahn; Zhen Huan Hu; Elias Jabbour; Srdan Verstovsek; Farhad Ravandi; Guillermo Garcia-Manero; Mohamed A. Kharfan-Dabaja; Nasheed M. Hossain; David I. Marks; Rammuriti T. Kamble; Yoshihiro Inamoto; Tamila Kindwall-Keller; Ayman Saad; Mark R. Litzow; Bipin N. Savani; Gregory A. Hale; Ulrike Bacher; Aaron T. Gerds; Jane L. Liesveld; Celalettin Ustun; Richard F. Olsson; Andrew Daly; Michael R. Grunwald; Melhem Solh; Zachariah DeFilipp; Mahmoud Aljurf; Baldeep Wirk; Gorgun Akpek; Taiga Nishihori; Jan Cerny; Sachiko Seo; Jack W. Hsu; Richard Champlin; Marcos de Lima; Edwin Alyea; Uday Popat; Ronald Sobecks; Bart L. Scott; Hagop Kantarjian; Jorge Cortes; Wael Saber

doi:10.1080/10428194.2020.1783444

Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients

Bei Hu, Xiao Lin, Hans C. Lee, Xuelin Huang, Rebecca S.Slack Tidwell, Kwang Woo Ahn, Zhen Huan Hu, Elias Jabbour, Srdan Verstovsek, Farhad Ravandi, Guillermo Garcia-Manero, Mohamed A. Kharfan-Dabaja, Nasheed M. Hossain, David I. Marks, Rammuriti T. Kamble, Yoshihiro Inamoto, Tamila Kindwall-Keller, Ayman Saad, Mark R. Litzow, Bipin N. SavaniGregory A. Hale, Ulrike Bacher, Aaron T. Gerds, Jane L. Liesveld, Celalettin Ustun, Richard F. Olsson, Andrew Daly, Michael R. Grunwald, Melhem Solh, Zachariah DeFilipp, Mahmoud Aljurf, Baldeep Wirk, Gorgun Akpek, Taiga Nishihori, Jan Cerny, Sachiko Seo, Jack W. Hsu, Richard Champlin, Marcos de Lima, Edwin Alyea, Uday Popat, Ronald Sobecks, Bart L. Scott, Hagop Kantarjian, Jorge Cortes, Wael Saber

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

While TKI are the preferred first-line treatment for chronic phase (CP) CML, alloHCT remains an important consideration. The aim is to estimate residual life expectancy (RLE) for patients initially diagnosed with CP CML based on timing of alloHCT or continuation of TKI in various settings: CP1 CML, CP2 + [after transformation to accelerated phase (AP) or blast phase (BP)], AP, or BP. Non-transplant cohort included single-institution patients initiating TKI and switched TKI due to failure. CIBMTR transplant cohort included CML patients who underwent HLA sibling matched (MRD) or unrelated donor (MUD) alloHCT. AlloHCT appeared to shorten survival in CP1 CML with overall mortality hazard ratio (HR) for alloHCT of 2.4 (95% CI 1.2–4.9; p =.02). In BP CML, there was a trend toward higher survival with alloHCT; HR = 0.7 (0.5–1.1; p =.099). AlloHCT in CP2 + [HR = 2.0 (0.8–4.9), p =.13] and AP [HR = 1.1 (0.6–2.1); p =.80] is less clear and should be determined on a case-by-case basis.

Original language	English (US)
Pages (from-to)	2811-2820
Number of pages	10
Journal	Leukemia and Lymphoma
DOIs	https://doi.org/10.1080/10428194.2020.1783444
State	Published - 2020

Keywords

Chronic myeloid leukemia
allogeneic stem cell transplant
tyrosine kinase inhibitors

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

MD Anderson CCSG core facilities

Biostatistics Resource Group

Access to Document

10.1080/10428194.2020.1783444

Cite this

Hu, B., Lin, X., Lee, H. C., Huang, X., Tidwell, R. S. S., Ahn, K. W., Hu, Z. H., Jabbour, E., Verstovsek, S., Ravandi, F., Garcia-Manero, G., Kharfan-Dabaja, M. A., Hossain, N. M., Marks, D. I., Kamble, R. T., Inamoto, Y., Kindwall-Keller, T., Saad, A., Litzow, M. R., ... Saber, W. (2020). Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. Leukemia and Lymphoma, 2811-2820. https://doi.org/10.1080/10428194.2020.1783444

Hu, B, Lin, X, Lee, HC , Huang, X , Tidwell, RSS, Ahn, KW, Hu, ZH, Jabbour, E, Verstovsek, S, Ravandi, F , Garcia-Manero, G, Kharfan-Dabaja, MA, Hossain, NM, Marks, DI, Kamble, RT, Inamoto, Y, Kindwall-Keller, T, Saad, A, Litzow, MR, Savani, BN, Hale, GA, Bacher, U, Gerds, AT, Liesveld, JL, Ustun, C, Olsson, RF, Daly, A, Grunwald, MR, Solh, M, DeFilipp, Z, Aljurf, M, Wirk, B, Akpek, G, Nishihori, T, Cerny, J, Seo, S, Hsu, JW, Champlin, R, de Lima, M, Alyea, E, Popat, U, Sobecks, R, Scott, BL, Kantarjian, H, Cortes, J & Saber, W 2020, 'Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients', Leukemia and Lymphoma, pp. 2811-2820. https://doi.org/10.1080/10428194.2020.1783444

@article{648b84357cd04225be4deb9075ceeb5b,

title = "Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients",

abstract = "While TKI are the preferred first-line treatment for chronic phase (CP) CML, alloHCT remains an important consideration. The aim is to estimate residual life expectancy (RLE) for patients initially diagnosed with CP CML based on timing of alloHCT or continuation of TKI in various settings: CP1 CML, CP2 + [after transformation to accelerated phase (AP) or blast phase (BP)], AP, or BP. Non-transplant cohort included single-institution patients initiating TKI and switched TKI due to failure. CIBMTR transplant cohort included CML patients who underwent HLA sibling matched (MRD) or unrelated donor (MUD) alloHCT. AlloHCT appeared to shorten survival in CP1 CML with overall mortality hazard ratio (HR) for alloHCT of 2.4 (95% CI 1.2–4.9; p =.02). In BP CML, there was a trend toward higher survival with alloHCT; HR = 0.7 (0.5–1.1; p =.099). AlloHCT in CP2 + [HR = 2.0 (0.8–4.9), p =.13] and AP [HR = 1.1 (0.6–2.1); p =.80] is less clear and should be determined on a case-by-case basis.",

keywords = "Chronic myeloid leukemia, allogeneic stem cell transplant, tyrosine kinase inhibitors",

author = "Bei Hu and Xiao Lin and Lee, {Hans C.} and Xuelin Huang and Tidwell, {Rebecca S.Slack} and Ahn, {Kwang Woo} and Hu, {Zhen Huan} and Elias Jabbour and Srdan Verstovsek and Farhad Ravandi and Guillermo Garcia-Manero and Kharfan-Dabaja, {Mohamed A.} and Hossain, {Nasheed M.} and Marks, {David I.} and Kamble, {Rammuriti T.} and Yoshihiro Inamoto and Tamila Kindwall-Keller and Ayman Saad and Litzow, {Mark R.} and Savani, {Bipin N.} and Hale, {Gregory A.} and Ulrike Bacher and Gerds, {Aaron T.} and Liesveld, {Jane L.} and Celalettin Ustun and Olsson, {Richard F.} and Andrew Daly and Grunwald, {Michael R.} and Melhem Solh and Zachariah DeFilipp and Mahmoud Aljurf and Baldeep Wirk and Gorgun Akpek and Taiga Nishihori and Jan Cerny and Sachiko Seo and Hsu, {Jack W.} and Richard Champlin and {de Lima}, Marcos and Edwin Alyea and Uday Popat and Ronald Sobecks and Scott, {Bart L.} and Hagop Kantarjian and Jorge Cortes and Wael Saber",

note = "Publisher Copyright: {\textcopyright} 2020, {\textcopyright} 2020 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2020",

doi = "10.1080/10428194.2020.1783444",

language = "English (US)",

pages = "2811--2820",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients

AU - Hu, Bei

AU - Lin, Xiao

AU - Lee, Hans C.

AU - Huang, Xuelin

AU - Tidwell, Rebecca S.Slack

AU - Ahn, Kwang Woo

AU - Hu, Zhen Huan

AU - Jabbour, Elias

AU - Verstovsek, Srdan

AU - Ravandi, Farhad

AU - Garcia-Manero, Guillermo

AU - Kharfan-Dabaja, Mohamed A.

AU - Hossain, Nasheed M.

AU - Marks, David I.

AU - Kamble, Rammuriti T.

AU - Inamoto, Yoshihiro

AU - Kindwall-Keller, Tamila

AU - Saad, Ayman

AU - Litzow, Mark R.

AU - Savani, Bipin N.

AU - Hale, Gregory A.

AU - Bacher, Ulrike

AU - Gerds, Aaron T.

AU - Liesveld, Jane L.

AU - Ustun, Celalettin

AU - Olsson, Richard F.

AU - Daly, Andrew

AU - Grunwald, Michael R.

AU - Solh, Melhem

AU - DeFilipp, Zachariah

AU - Aljurf, Mahmoud

AU - Wirk, Baldeep

AU - Akpek, Gorgun

AU - Nishihori, Taiga

AU - Cerny, Jan

AU - Seo, Sachiko

AU - Hsu, Jack W.

AU - Champlin, Richard

AU - de Lima, Marcos

AU - Alyea, Edwin

AU - Popat, Uday

AU - Sobecks, Ronald

AU - Scott, Bart L.

AU - Kantarjian, Hagop

AU - Cortes, Jorge

AU - Saber, Wael

PY - 2020

Y1 - 2020

N2 - While TKI are the preferred first-line treatment for chronic phase (CP) CML, alloHCT remains an important consideration. The aim is to estimate residual life expectancy (RLE) for patients initially diagnosed with CP CML based on timing of alloHCT or continuation of TKI in various settings: CP1 CML, CP2 + [after transformation to accelerated phase (AP) or blast phase (BP)], AP, or BP. Non-transplant cohort included single-institution patients initiating TKI and switched TKI due to failure. CIBMTR transplant cohort included CML patients who underwent HLA sibling matched (MRD) or unrelated donor (MUD) alloHCT. AlloHCT appeared to shorten survival in CP1 CML with overall mortality hazard ratio (HR) for alloHCT of 2.4 (95% CI 1.2–4.9; p =.02). In BP CML, there was a trend toward higher survival with alloHCT; HR = 0.7 (0.5–1.1; p =.099). AlloHCT in CP2 + [HR = 2.0 (0.8–4.9), p =.13] and AP [HR = 1.1 (0.6–2.1); p =.80] is less clear and should be determined on a case-by-case basis.

AB - While TKI are the preferred first-line treatment for chronic phase (CP) CML, alloHCT remains an important consideration. The aim is to estimate residual life expectancy (RLE) for patients initially diagnosed with CP CML based on timing of alloHCT or continuation of TKI in various settings: CP1 CML, CP2 + [after transformation to accelerated phase (AP) or blast phase (BP)], AP, or BP. Non-transplant cohort included single-institution patients initiating TKI and switched TKI due to failure. CIBMTR transplant cohort included CML patients who underwent HLA sibling matched (MRD) or unrelated donor (MUD) alloHCT. AlloHCT appeared to shorten survival in CP1 CML with overall mortality hazard ratio (HR) for alloHCT of 2.4 (95% CI 1.2–4.9; p =.02). In BP CML, there was a trend toward higher survival with alloHCT; HR = 0.7 (0.5–1.1; p =.099). AlloHCT in CP2 + [HR = 2.0 (0.8–4.9), p =.13] and AP [HR = 1.1 (0.6–2.1); p =.80] is less clear and should be determined on a case-by-case basis.

KW - Chronic myeloid leukemia

KW - allogeneic stem cell transplant

KW - tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85089288816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089288816&partnerID=8YFLogxK

U2 - 10.1080/10428194.2020.1783444

DO - 10.1080/10428194.2020.1783444

M3 - Article

C2 - 32662346

AN - SCOPUS:85089288816

SN - 1042-8194

SP - 2811

EP - 2820

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

ER -

Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients

Abstract

Keywords

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this